Ignite Creation Date:
2024-05-05 @ 5:12 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00406146
Status:
UNKNOWN
Last Update Posted:
2006-12-04
First Post:
2006-11-13
Brief Title:
AmodiaquineArtesunate vs Artemether-Lumefantrine for Uncomplicated Malaria in Ghanaian Children
Sponsor:
University of Ghana Medical School
Organization:
University of Ghana Medical School
Study Overview
Official Title:
None
Status:
UNKNOWN
Status Verified Date:
2006-11
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Artemisinin combination therapies ACT are currently recommended for malaria treatment Artemether-lumefantrineA-L and Artesunateamodiaquine AA have been the most commonly adopted of the recommended ACT regimens In Ghana AA is the current first-line antimalarial treatment in Ghana but there has been 1 efficacy report of this regimen in Ghana till date Moreover the safety of repeated treatments with ACT has been little studied This study aims to evaluate the efficacy of AA vs A-L as well as the safety of repeated treatments of these regimens in a longitudinal trial in which recruited children will be followed up for 1 year
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| GHN-202-M03-M-00 | None | None | None |